Abstract: Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Abstract: A pair of eye goggles is provided. The pair of eye goggles includes a nosepiece fittable over a portion of a wearer's face, the nosepiece comprising one or more strands, at least a portion of the nosepiece comprising a phase change material, wherein a shape of the nosepiece changes upon an application of an energy to the phase changing portion to conform to the face; and a pair of eyepieces connected to the nosepiece.

Abstract: An articulated chin rest is assembly is provided for supporting the chin of a patient under monitored anesthesia care, sedation, general anesthesia, or other medical procedure to ensure that their airway is unobscured. The assembly may comprise a clamp adaptable to grip a variety of structures, a first and a second length of rigid material sequentially and rotatably connected to the clamp, and a chin rest finally rotatably connected to the second length of rigid material. Means for rotatably linking the clamp, first and second lengths of rigid material, and chin rest allow each element to rotate in three dimensional space so that the assembly mechanically mimics, and is ultimately usable in place of, an anesthesiologist's hand for tilting the patient's head and securely supporting the patient's chin.

Abstract: The subject of the invention is a medical device for foot support related to a mechanism for attaching a calf support of the birthing bed, comprising a calf support (3) connected to a foot support (2) and a ball joint (5) connecting the calf support (3) and the foot support (2), wherein the ball part (5) comprises a pin (6) of the ball joint (5), a ball part (7) of the ball joint (5) and a housing (8), wherein the ball part (7) of the ball joint (5) is arranged in the housing (8), the medical device further comprising a pressing element (9) and a pre-biased spring (10), characterized in that the pre-biased spring (10) is arranged between the pressing element (9) and the fixed part (11) of the calf support (3), wherein at the end distant from the ball part (7) of the ball joint (5) the pre-biased spring abuts to adjacent fixed part (11) of the calf support (3) and at the end near the ball part (7) of the ball joint (5) it abuts to the movable pressing element (9) which is connected with the control member.

Abstract: An electric power assist device includes a processor including hardware. The processor assists human power input from a user to a drive member with power of a motor, determines whether a current position is located outdoors using a signal from a sensor, and when determination is made that the current position is located outdoors, reduces an assist amount by the motor as compared with a case where the current position is located indoors.

Abstract: A frame module includes a frame configured to enclose a portion of a user, and at least one reinforcement belt of which both end portions are connected to both sides of the frame, thereby restricting a splaying level of the frame in a predetermined direction.

Abstract: A massage gun and a massage gun extension arm having a handle end that can extend through a first bend and further extend to terminate at an attachment end. Various attachment mechanisms may be used to connect the massage gun extension arm to the massage gun, or to a separate massage tool. The massage gun extension arm can include a telescoping adjustment along the portion between the bend and the handle end, or between the bend and the attachment end. In some embodiments, the arm, between the bend and the handle end, can include a disconnection, the disconnection being in the form of a pivoting bend or in a complete disconnection of parts. This disconnection allows for ease of transport, with the massage gun extension arm stored and carried in a relatively small footprint.

Abstract: A walker that includes a first frame having first and second legs, a second frame having first and second legs, one or more support bars connecting the first leg of the first frame to the first leg of the second frame; and a foldable or stowable foot rest.

Abstract: A walker for use by a mobility impaired disabled user. The walker supports the user while moving them through a set of movements correlating to a walking motion. The walker includes an exoskeleton, a power source in the form of a battery pack or other similar onboard power pack together with its associated power supply cables, and a control system The exoskeleton includes a rigid pelvic support member including a pelvic harness and a pair of leg structures Each of the leg structures comprise an upper leg structural member, a lower leg structural member, a foot member, a main hip actuator, a knee actuator and a main foot actuator.

Abstract: A retractable walker is disclosed, including left armrest component, a right armrest component, a seat, two front support members, and two rear support members. The left armrest component and the right armrest component are configured to be disposed at left and right and connected to each other in a left and right retractable adjustment. The seat includes a horizontal support frame and a seat plate, the horizontal support frame has a left and right retractable structure, and left and right ends of the horizontal support frame are configured to be mounted to the left armrest component and the right armrest component for connection respectively. The retractable walker can be retracted to adjust sizes, thereby applicable to different tall and short, fat and thin populations, which can greatly improve versatility of this product, more convenient to use.

Abstract: Methods and devices are described, such as for chest compression depth measurement for CPR performed on infants and for allowing active decompression of a patient's chest during a release phase of a chest compression cycle. An anterior segment of a resilient wrap-around structure may be positioned on the patient's sternum, including a first motion sensor. A posterior segment of the resilient wrap-around structure may be positioned on the patient's back, including a second motion sensor. Chest compressions may be provided such that the first motion sensor moves in fixed relation with the patient's sternum and the second sensor moves in fixed relation with the patient's back. Active decompression may be allowed for, including the resilient wrap-around structure exerting an expansive force on the patient's chest wall during a release phase of a chest compression cycle and hastening expansion of the patient's chest during the release phase.

Abstract: An example of a system for providing emergency care to a patient includes an automated chest compression device configured to engage the patient at the patient's sternum to provide multiple chest compression cycles to the patient's sternum, an automated mechanical ventilation device to induce negative pressure ventilation, and a controller operably coupled to the automated chest compression device and the automated mechanical ventilation device and including one or more processors configured to control the automated chest compression device to cyclically perform chest compressions, and control the automated mechanical ventilation device to cyclically induce the negative pressure ventilation out-of-phase with the chest compressions such that the automated mechanical ventilation device cyclically induces the negative pressure ventilation prior to each compression of the patient's sternum.

Abstract: A system and method for determining CPR induced chest compression depth using two sensors while accounting for different orientations of the two sensors.

Abstract: A massage chair capable of massaging the front body region is proposed. In the massage chair, one end is rotatably coupled to the backrest part and the backrest part for supporting the user's back, and includes a front massage part for massaging the user's abdomen or chest. According to the present configuration, there is proposed a massage chair capable of performing massage even in a front body region of a person to be treated, such as a chest or an abdomen.

Abstract: A therapy system that includes a patient support apparatus and a pneumatic therapy device that is coupleable to the patient support apparatus. The therapy device may receive power and air flow from the patient support apparatus.

Abstract: A package that is configured to store and dispense fluids. The package includes a container and a dosing dispenser for closing an opening to the container. The dosing dispenser includes a closure removably coupled to the container and an anti-suction valve fixed to the container that is configured to minimize formation of a complete seal between a user's mouth and an upper surface of the anti-suction valve so that sufficient suction to remove fluid from the container is blocked.

Abstract: A medical product includes a bladder, a filtration device, and a sterile product concentrate. The bladder has a perimeter seal and defining a sterile chamber. The filtration device includes a stem and a filter membrane disposed in line with the stem. The stem extends through the perimeter seal and has an inlet end accessible from outside of the perimeter seal and an outlet end in fluid communication with the sterile chamber. The filter membrane can have a nominal pore size in a range of approximately 0.1 ?m to approximately 0.5 ?m, wherein the filter membrane is shaped as a hollow fiber with a wall and pores residing in the wall of the fiber. The sterile product concentrate is disposed in the sterile chamber and adapted to be reconstituted by the introduction of a pharmaceutical fluid into the chamber through the filtration device.

Abstract: In a vacuum heat insulating double walled container 1, adsorbent blocks 30 are formed in block, and each of the adsorbent blocks 30 disposed on the peripheral surface of a sample storage container 25 is placed on a partition plate 27. Moreover, an inner container 10 is hang in an outer container 3 using a connecting tube 20 formed of a thin material having an uneven outer peripheral surface, and a heat insulating tube 40 is disposed on the inner surface of the connecting tube 20. Further, as to a workpiece carrier 50 as a fixing device, a carrier guide 52 is in close contact with the heat insulating tube 40, and a plate-like portion 54 and a workpiece storage portion 51 are disposed in a non-contact state with respect to the sample storage container 25.

Abstract: Various aspects of the subject disclosure relate to a compounder system having a cartridge that includes fluid pathways controllable by valves of the cartridge. A pump component within the cartridge is actuable to move fluid through the controllable fluid pathways. The cartridge includes a needleless fluid port and a needleless vent port for fluid coupling to a vial via a vial puck. The vial puck includes corresponding needleless fluid and vent ports and a cannula. The cannula is extendible, by insertion of a protrusion on the cartridge into a shaft of the vial puck, into the vial to couple the vial to the needleless fluid and vent ports.

Abstract: The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof.

Abstract: A muscular atrophy-inducing agent containing, as an active ingredient, a hypometabolism-inducing substance selected from the group consisting of 3-iodothyronamine (T1AM), [D-Ala2,D-Leu5] enkephalin (DADLE), 5?-adenosine monophosphate (5?-AMP), and hydrogen sulfide (H2S), and a method for preventing or treating muscular hypertrophy; and a method for shrinking facial muscle are proposed. The muscular atrophy study model can provide a study model for an economic muscular atrophy study by using a hypometabolism-inducing substance which can be mass-produced, has an effect which may be usefully used by verification for screening of a drug for preventing or treating muscular atrophy, and can be usefully used as a compositions for preventing or treating muscular hypertrophy and a composition for facial muscle shrinkage through the muscular atrophy effect.

Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Abstract: The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.

Abstract: Disclosed are methods of treating seizures in a subject. The methods can include administering to the subject in need thereof an effective amount of uridine source and a ketogenic composition including a ketogenic compound.

Abstract: Disclosed are gastroretentive, sustained-release tablet formulations comprising an active agent, such as pregabalin or a pharmaceutically acceptable form thereof, crospovidone, and a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer.

Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD+ precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.

Abstract: The invention relates to animal feeds and feed premixes containing synergistically effective amounts of betaine hydrochloride and a phytase.

Abstract: The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5? reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

Abstract: The invention relates to bismuth-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods for treating a topical wound, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a bismuth-thiol compound, wherein the composition is applied to the infection. Methods for treating microbial infections such as diabetic foot infections are also provided.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

Abstract: Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity.

Abstract: Compositions comprising an active oxygen-responsive antioxidant crystal, methods of making them, and methods for controlling the dissolution rate and/or altering the crystallization behavior of an antioxidant are disclosed. The crystals comprise an antioxidant and a disulfide- or diselenide-crosslinked polymer that is adsorbed onto a surface of the antioxidant. Upon exposure to an active-oxygen stimulus, the polymer de-crosslinks to release the antioxidant from the composition in an amount effective to counteract the stimulus. While prior approaches to altering dissolution rates have relied on passive zero- or first-order kinetics that are independent of ROS levels, the inventive compositions actively respond by releasing antioxidant in an amount proportional to the concentration of active-oxygen species present. The crystallization methods are simple and scalable.

Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

Abstract: The present invention relates to a composition of a compound of general formula (A), a pharmaceutically acceptable salt or a prodrug, and a preparation method therefor.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R1, R2a, and R2b are defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.

Abstract: This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.

Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.

Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.

Abstract: Adenosine receptor active compounds including 1,2,3,6,8-pentasubstituted indolizines and methods of using the same for inhibiting adenosine receptor activity are provided. These methods can be used to treat one or more pathological conditions of the central and peripheral nervous systems, such as but not limited to allergies, inflammation, glaucoma, brain ischemia, renal fibrosis, cancer, rheumatoid arthritis, psoriasis fatty liver diseases, stroke, pain, and any combination thereof.

Abstract: The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.

Abstract: Provided herein are solution formulations of CX-011 and related methods for making solution formulations of CX-011. Also provided are methods of treating an inflammatory disorder, such as osteoarthritis, or cancer in a subject in need thereof by administering an effective amount of the solution formulations of CX-011.

Abstract: A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

Abstract: A 6?-(4-bromophenyl)-2?-methoxy-3,4?-bipyridine-3?-carbonitrile as antioxidant compound, its synthesis, and its use as an antioxidant agent.

Abstract: The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.

Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):